Overview

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on the results of MRD evaluation.
Phase:
Phase 4
Details
Lead Sponsor:
Johann Wolfgang Goethe University Hospital
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany)
German Federal Ministry of Education and Research
Treatments:
6-Mercaptopurine
Asparaginase
Cladribine
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Fludarabine
Idarubicin
Mercaptopurine
Methotrexate
Prednisolone
Thioguanine
Vincristine
Vindesine